Enanta Pharmaceuticals stock fell 2.78 percent on October 5

Published on 10/05/2026 at 23:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Enanta Pharmaceuticals stock traded at USD 12.60 on October 5, down 2.78 percent from the prior close. Q3 revenue was USD 14.36 million, below consensus.

ENTA, US29251M1062, Illustration mit AI erstellt.

Enanta Pharmaceuticals (ISIN US29251M1062) was last at USD 12.60 on October 5, 2026, down 2.78 percent from the prior close of USD 12.96. The latest analyst update kept attention on the company's weak fiscal third-quarter figures and its development pipeline.

Analyst view stays positive

According to MarketBeat on October 3, Wall Street Zen upgraded Enanta from Sell to Hold. The report also cited three Buy ratings and one Sell rating, producing a Moderate Buy consensus with a USD 19.00 average price target.

The consensus target lies 50.8 percent above the October 5 price of USD 12.60. H.C. Wainwright separately maintained a Buy rating and a USD 20.00 target in a report dated September 23, according to MarketBeat.

Revenue misses the estimate

Enanta's fiscal third quarter ended June 30, 2026, with revenue of USD 14.36 million and a consolidated net loss of USD 19.5 million. The revenue figure was 20.97 percent below the USD 16.76 million consensus estimate, according to Zacks Investment Research.

The quarter produced an adjusted loss of USD 0.67 per share, compared with a consensus loss of USD 0.37 per share. Revenue was also below the USD 18.31 million reported for the year-earlier quarter, showing that lower royalty income remains a central financial pressure.

Pipeline supports the valuation case

Enanta is a clinical-stage biotechnology company developing small-molecule therapies for viral infections and immunological diseases. Its current programs include zelicapavir for respiratory syncytial virus and early-stage immunology candidates targeting KIT, STAT6 and MRGPRX2, according to the company's investor-relations overview.

The financial profile remains research intensive: operating cash flow was negative USD 9.972 million in the quarter ended June 30, 2026, while cash and cash equivalents stood at USD 33.419 million. For investors, the valuation argument therefore depends on clinical progress and future product revenue rather than current profitability.

Stock remains below yearly high

Enanta Pharmaceuticals stock was last at USD 12.60 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, with a session range of USD 12.53 to USD 12.97. Its 52-week range was USD 10.20 to USD 17.15, and its market capitalization stood at USD 366.4 million.